LADENBURG THALM/SH SH lowered shares of Zynex (NASDAQ:ZYXI – Free Report) from a buy rating to a neutral rating in a report released on Wednesday morning, MarketBeat.com reports. Separately, HC ...
Royal Bank of Canada cut shares of Zynex (NASDAQ:ZYXI – Free Report) from an outperform rating to a sector perform rating in a research report sent to investors on Wednesday, Marketbeat.com reports.
Fintel reports that on March 12, 2025, Ladenburg Thalmann downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...
Fintel reports that on March 12, 2025, RBC Capital downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Outperform to ...
Zynex develops, manufactures, markets and sells medical devices used for nerve stimulation, pain management, and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry ...
Zynex specializes in non-invasive pain management and patient monitoring, with promising advancements. Read why I think ZYXI ...
Despite a net loss and TRICARE payment suspension, Zynex Inc (ZYXI) shows resilience with revenue growth and strategic ...
Zynex, Inc. ( NASDAQ:ZYXI ) just released its latest full-year report and things are not looking great. It wasn't ...
Zynex (ZYXI) stock drops as RBC Capital Market downgrades following the company's Q4 2024 earnings report. Read more here.
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ICU Medical (ICUI – Research Report) and ...
--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company’s ...
Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) investors concerning the Company's possible violations of federal ...